Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 15

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 15
---
 $
    112.80 – 201.60

    $
    132.13

     13 

There were no stock option grants during the three
months ended June 30, 2025 and 2024. There were 71,432 RSUs granted during the three months June 30, 2025. The weighted average grant
date fair value of RSUs granted during the three months ended June 30, 2025 was $2.80. There were no stock option exercises during the
three months ended June 30, 2025 and 2024. On June 30, 2025, our outstanding stock options had no intrinsic value, since the closing share
price on that date of $1.20 per share was below the exercise price of our outstanding stock options.

The table below summarizes nonvested stock options as of June 30, 2025
and changes during the three months ended June 30, 2025.

    Schedule of non vested stock options

    Shares

    Weighted Average Grant Date Fair Value

    Nonvested stock options at April 1, 2025

    751

    $
    1.37

    Vested

    (205
    )
     
    $
    1.37

    Forfeited

    –

    Nonvested stock options at June 30, 2025

    546

The detail of the options outstanding and exercisable as of June 30, 2025
is as follows:

    Schedule of options outstanding and exercisable

    Options Outstanding

    Options Exercisable

    Exercise Prices

    Number 
Outstanding

    Weighted 
Average 
Remaining 
Life (Years)

    Weighted 
Average 
Exercise 
Price

    Number 
Outstanding

    Weighted 
Average 
Exercise 
Price

    $
    102.40 – 112.80

    5,034

    5.97 years

    $
    109.17

    4,488

    $
    108.73

    $
    201.60

    1,512

    5.52 years

    $
    201.60

    1,512

    $
    201.60

    6,546

    6,000

We recorded stock-based compensation expense related
to RSU issuances and to options granted totaling $72,442 and